Real-World Impact of CAR-T Therapy on DLBCL: Insights & Future Research | Lisa Herms, PhD | #ASH24

Real-World Impact of CAR-T Therapy on DLBCL: Insights & Future Research | Lisa Herms, PhD | #ASH24

Myeloma: Real-World Use of Bispecific Antibodies in Community Oncology | Lisa Herms, PhD | #ASH24

Myeloma: Real-World Use of Bispecific Antibodies in Community Oncology | Lisa Herms, PhD | #ASH24

KRd vs RD: Reducing Progression in High-Risk Smoldering Myeloma | Annemiek Broijl, PhD | #ASH24

KRd vs RD: Reducing Progression in High-Risk Smoldering Myeloma | Annemiek Broijl, PhD | #ASH24

KRd vs RD: Reducing Progression in High-Risk Smoldering Myeloma

Side Effect Severity & Decision-Making Autonomy in Myeloma | Jay Hydren, PhD, CSCS | #ASH24

Side Effect Severity & Decision-Making Autonomy in Myeloma | Jay Hydren, PhD, CSCS | #ASH24

Myeloma Patient Experiences with Talquetamab | Jay Hydren, PhD, CSCS | #ASH24

Myeloma Patient Experiences with Talquetamab | Jay Hydren, PhD, CSCS | #ASH24

Myeloma Updates: High-Risk Smoldering, MRD, IVIG, and Maintenance | Natalie Callander, MD | #ASH24

Myeloma Updates: High-Risk Smoldering, MRD, IVIG, and Maintenance | Natalie Callander, MD | #ASH24

Achieving MRD Negativity: Iberdomide Study for Myeloma Post-AHCT | Natalie Callander, MD | #ASH24

Achieving MRD Negativity: Iberdomide Study for Myeloma Post-AHCT | Natalie Callander, MD | #ASH24

Study Shows Promise for Non-Invasive MRD Testing for Myeloma Patients | Dory Abelman PhD(c) | #ASH24

Study Shows Promise for Non-Invasive MRD Testing for Myeloma Patients | Dory Abelman PhD(c) | #ASH24

Novel CAR-T Attacks New Target in Relapsed LBCL | Anne Kramer, MD, PhD | #ASH24

Novel CAR-T Attacks New Target in Relapsed LBCL | Anne Kramer, MD, PhD | #ASH24

Fludarabine vs. Bendamustine Lymphodepletion Prior to CAR-T for LBCL | Alaa Ali, MD | #ASH24

Fludarabine vs. Bendamustine Lymphodepletion Prior to CAR-T for LBCL | Alaa Ali, MD | #ASH24

Rituximab for Low Tumor Burden Follicular Lymphoma | Noriko Fukuhara MD, PhD | #ASH24

Rituximab for Low Tumor Burden Follicular Lymphoma | Noriko Fukuhara MD, PhD | #ASH24

Positive Loncastuximab & Rituximab Results in R/R Follicular Lymphoma | Juan Alderuccio, MD | #ASH24